Arvinas (ARVN) Competitors

$9.44 -0.43 (-4.40%)

Closing price 03:59 PM Eastern

Extended Trading

$9.42 -0.02 (-0.17%)

As of 04:10 PM Eastern

ARVN vs. IMNM, IRON, ELVN, VERA, and ADMA

Should you buy Arvinas stock or one of its competitors? MarketBeat compares Arvinas with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arvinas include Immunome (IMNM), Disc Medicine (IRON), Enliven Therapeutics (ELVN), Vera Therapeutics (VERA), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.

How does Arvinas compare to Immunome?

Arvinas (NASDAQ:ARVN) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Immunome has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Immunome	N/A	-57.71%	-52.69%

Arvinas has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Immunome has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market.

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Arvinas presently has a consensus target price of $15.14, suggesting a potential upside of 60.48%. Immunome has a consensus target price of $33.45, suggesting a potential upside of 51.91%. Given Arvinas' higher probable upside, equities research analysts plainly believe Arvinas is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	3 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.40
Immunome	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Arvinas has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$89.40M	6.81	-$80.80M	-$3.32	N/A
Immunome	$6.94M	359.36	-$212.39M	-$2.42	N/A

In the previous week, Arvinas had 14 more articles in the media than Immunome. MarketBeat recorded 26 mentions for Arvinas and 12 mentions for Immunome. Immunome's average media sentiment score of 0.97 beat Arvinas' score of 0.49 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	11 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunome	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arvinas beats Immunome on 9 of the 16 factors compared between the two stocks.

How does Arvinas compare to Disc Medicine?

Arvinas (NASDAQ:ARVN) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Arvinas has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$89.40M	6.81	-$80.80M	-$3.32	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Arvinas presently has a consensus target price of $15.14, suggesting a potential upside of 60.48%. Disc Medicine has a consensus target price of $105.30, suggesting a potential upside of 51.02%. Given Arvinas' higher probable upside, equities research analysts plainly believe Arvinas is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	3 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.40
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Arvinas has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 3.8% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Arvinas had 11 more articles in the media than Disc Medicine. MarketBeat recorded 26 mentions for Arvinas and 15 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.49 beat Arvinas' score of 0.49 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	11 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Disc Medicine has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Disc Medicine's return on equity of -36.94% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Disc Medicine	N/A	-36.94%	-33.88%

Summary

Arvinas beats Disc Medicine on 10 of the 15 factors compared between the two stocks.

How does Arvinas compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Arvinas has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Arvinas	$89.40M	6.81	-$80.80M	-$3.32	N/A

Enliven Therapeutics currently has a consensus target price of $53.17, suggesting a potential upside of 23.40%. Arvinas has a consensus target price of $15.14, suggesting a potential upside of 60.48%. Given Arvinas' higher possible upside, analysts plainly believe Arvinas is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Arvinas	3 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.40

Enliven Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by insiders. Comparatively, 7.3% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Arvinas had 9 more articles in the media than Enliven Therapeutics. MarketBeat recorded 26 mentions for Arvinas and 17 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.98 beat Arvinas' score of 0.49 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	11 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Enliven Therapeutics' return on equity of -21.04% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Arvinas	-247.54%	-44.38%	-28.38%

Summary

Enliven Therapeutics and Arvinas tied by winning 8 of the 16 factors compared between the two stocks.

How does Arvinas compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Vera Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Arvinas	-247.54%	-44.38%	-28.38%

Arvinas has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Arvinas	$89.40M	6.81	-$80.80M	-$3.32	N/A

Vera Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

Vera Therapeutics currently has a consensus target price of $79.60, suggesting a potential upside of 100.93%. Arvinas has a consensus target price of $15.14, suggesting a potential upside of 60.48%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Vera Therapeutics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Arvinas	3 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Arvinas had 7 more articles in the media than Vera Therapeutics. MarketBeat recorded 26 mentions for Arvinas and 19 mentions for Vera Therapeutics. Arvinas' average media sentiment score of 0.49 beat Vera Therapeutics' score of 0.18 indicating that Arvinas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arvinas	11 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Arvinas beats Vera Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Arvinas compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

ADMA Biologics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

ADMA Biologics has a net margin of 32.43% compared to Arvinas' net margin of -247.54%. ADMA Biologics' return on equity of 39.98% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Arvinas	-247.54%	-44.38%	-28.38%

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ADMA Biologics has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$509.86M	3.97	$146.93M	$0.68	12.50
Arvinas	$89.40M	6.81	-$80.80M	-$3.32	N/A

ADMA Biologics currently has a consensus target price of $19.00, suggesting a potential upside of 123.61%. Arvinas has a consensus target price of $15.14, suggesting a potential upside of 60.48%. Given ADMA Biologics' higher probable upside, equities research analysts plainly believe ADMA Biologics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Arvinas	3 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Arvinas had 9 more articles in the media than ADMA Biologics. MarketBeat recorded 26 mentions for Arvinas and 17 mentions for ADMA Biologics. Arvinas' average media sentiment score of 0.49 beat ADMA Biologics' score of 0.26 indicating that Arvinas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	3 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arvinas	11 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ADMA Biologics beats Arvinas on 8 of the 15 factors compared between the two stocks.

Get Arvinas News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARVN vs. The Competition

Export

Metric	Arvinas	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$608.82M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-2.84	18.81	20.87	25.61
Price / Sales	6.81	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	1.58	6.75	9.86	6.71
Net Income	-$80.80M	$24.11M	$3.55B	$333.77M
7 Day Performance	-7.40%	0.11%	-0.26%	0.40%
1 Month Performance	-14.22%	0.87%	1.39%	4.03%
1 Year Performance	55.45%	78.18%	41.07%	36.33%

Arvinas Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARVN Arvinas	2.7824 of 5 stars	$9.44 -4.4%	$15.14 +60.5%	+56.9%	$608.82M	$89.40M	N/A	420	Trending News Earnings Report Analyst Forecast Insider Trade
IMNM Immunome	3.5015 of 5 stars	$23.33 +2.6%	$33.45 +43.4%	+180.7%	$2.57B	$6.94M	N/A	40	Earnings Report Analyst Forecast Analyst Revision
IRON Disc Medicine	2.3961 of 5 stars	$67.64 +1.1%	$104.80 +54.9%	+51.1%	$2.55B	N/A	N/A	30	Analyst Forecast
ELVN Enliven Therapeutics	3.398 of 5 stars	$41.61 -0.2%	$43.40 +4.3%	+117.5%	$2.54B	N/A	N/A	50	Earnings Report Analyst Upgrade Analyst Revision
VERA Vera Therapeutics	3.283 of 5 stars	$35.51 +0.9%	$81.45 +129.4%	+81.4%	$2.51B	N/A	N/A	40	Trending News Earnings Report Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARVN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arvinas (ARVN) Competitors

ARVN vs. IMNM, IRON, ELVN, VERA, and ADMA

How does Arvinas compare to Immunome?

Summary

How does Arvinas compare to Disc Medicine?

Summary

How does Arvinas compare to Enliven Therapeutics?

Summary

How does Arvinas compare to Vera Therapeutics?

Summary

How does Arvinas compare to ADMA Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN vs. The Competition

Arvinas Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arvinas (ARVN) Competitors

ARVN vs. IMNM, IRON, ELVN, VERA, and ADMA

How does Arvinas compare to Immunome?

Is ARVN or IMNM more profitable?

Which has more risk & volatility, ARVN or IMNM?

Do institutionals and insiders have more ownership in ARVN or IMNM?

Do analysts prefer ARVN or IMNM?

Which has higher valuation & earnings, ARVN or IMNM?

Does the media favor ARVN or IMNM?

Summary

How does Arvinas compare to Disc Medicine?

Which has higher valuation & earnings, ARVN or IRON?

Do analysts prefer ARVN or IRON?

Which has more risk & volatility, ARVN or IRON?

Do institutionals and insiders have more ownership in ARVN or IRON?

Does the media favor ARVN or IRON?

Is ARVN or IRON more profitable?

Summary

How does Arvinas compare to Enliven Therapeutics?

Which has better valuation & earnings, ELVN or ARVN?

Do analysts recommend ELVN or ARVN?

Which has more risk & volatility, ELVN or ARVN?

Do insiders & institutionals have more ownership in ELVN or ARVN?

Does the media refer more to ELVN or ARVN?

Is ELVN or ARVN more profitable?

Summary

How does Arvinas compare to Vera Therapeutics?

Is VERA or ARVN more profitable?

Which has preferable earnings & valuation, VERA or ARVN?

Which has more volatility and risk, VERA or ARVN?

Do analysts recommend VERA or ARVN?

Does the media prefer VERA or ARVN?

Do institutionals & insiders have more ownership in VERA or ARVN?

Summary

How does Arvinas compare to ADMA Biologics?

Which has more volatility and risk, ADMA or ARVN?

Is ADMA or ARVN more profitable?

Do institutionals & insiders have more ownership in ADMA or ARVN?

Which has preferable earnings & valuation, ADMA or ARVN?

Do analysts recommend ADMA or ARVN?

Does the media prefer ADMA or ARVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN vs. The Competition

Arvinas Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools